NARF Inhibitors
Chemical inhibitors of NARF can be understood through their specific actions on various cellular signaling pathways that are integral to cell cycle regulation, proliferation, and survival. Alisertib, for example, targets Aurora kinase A, a kinase essential for mitotic progression. Inhibition of Aurora kinase A by Alisertib disrupts the cell cycle at a stage that is often regulated by proteins such as NARF. Similarly, Palbociclib (PD 0332991), which selectively inhibits CDK4 and CDK6, can arrest the cell cycle, leading to the suppression of cellular processes that NARF may regulate. Dasatinib, a Src family kinase inhibitor, disrupts downstream signaling pathways crucial for cellular functions, and such disruption can lead to the inhibition of NARF's activity in these processes. Omipalisib and AZD8055 both function as PI3K/mTOR inhibitors, attenuating the PI3K/Akt/mTOR signaling pathway, which is fundamental for cell growth and survival, thereby potentially inhibiting NARF's role in these pathways.
Further to this, Selumetinib and Trametinib, both MEK1/2 inhibitors, prevent the activation of the ERK pathway, which directly influences cell proliferation and survival where NARF may be involved. Sorafenib, by inhibiting RAF kinases, interrupts the MAPK/ERK signaling pathway, which can lead to the inhibition of NARF's associated activities. Lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, suppresses pathways related to cell growth, potentially inhibiting NARF activities in these pathways. Nutlin-3, by preventing the p53-MDM2 interaction, promotes the activation of p53, which can result in cell cycle arrest and subsequent inhibition of NARF-regulated cell cycle progression. Bosutinib and Pazopanib, both multi-tyrosine kinase inhibitors, by inhibiting their respective kinases, can suppress various cellular functions including angiogenesis and cell proliferation, thereby inhibiting NARF's associated activities in these processes.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MLN8237 | 1028486-01-2 | sc-394162 | 5 mg | $220.00 | ||
Alisertib is an Aurora kinase A inhibitor. Aurora kinase A is involved in the regulation of mitosis. Inhibition of Aurora kinase A can disrupt the cell cycle, which may lead to the inhibition of NARF due to its potential role in cellular proliferation. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib selectively inhibits cyclin-dependent kinases CDK4 and CDK6. As CDKs are essential for cell cycle progression, their inhibition can suppress cellular processes, leading to the inhibition of NARF activity related to cell cycle regulation. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor. By inhibiting Src kinases, it can disrupt downstream signaling, which is crucial for various cellular functions, thereby inhibiting NARF that is part of these signaling processes. | ||||||
GSK2126458 | 1086062-66-9 | sc-364503 sc-364503A | 2 mg 10 mg | $265.00 $1050.00 | ||
Omipalisib is a PI3K/mTOR inhibitor. By inhibiting these kinases, it can decrease signaling required for cell growth and survival, possibly leading to the inhibition of NARF activity in these pathways. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
Selumetinib is a MEK1/2 inhibitor. By inhibiting MEK1/2, it can prevent the activation of the ERK pathway, which is involved in cell proliferation and survival, thus inhibiting NARF activity associated with this pathway. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a RAF kinase inhibitor. By inhibiting RAF kinases, it can interrupt the MAPK/ERK signaling pathway, leading to the inhibition of NARF activity that may be associated with cell proliferation and differentiation. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib is a dual tyrosine kinase inhibitor targeting EGFR and HER-2. These receptors are involved in signaling pathways related to cell growth and division, and their inhibition can lead to the inhibition of NARF which may be involved in these pathways. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $62.00 $225.00 $779.00 | 24 | |
Nutlin-3 inhibits the interaction between p53 and MDM2. Since p53 is a tumor suppressor involved in cell cycle arrest, its activation can inhibit cell cycle progression and thereby inhibit NARF activity related to cell cycle regulation. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
AZD8055 is an mTOR inhibitor, and by inhibiting mTOR signaling, it can downregulate cellular processes like protein synthesis and cell growth, leading to the inhibition of NARF activity in these processes. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib inhibits MEK1/2, which are components of the MAPK/ERK pathway. This inhibition can lead to suppressed cell proliferation, potentially inhibiting NARF activity involved in cell growth signaling. | ||||||